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Abstract
Background: Human papilloma virus (HPV) is a known causative factor in oropharyngeal squamous cell cancer
(OPC). In this prospective study, we sought to define the risk of HPV transmission between OPC patients and their
sexual partners by performing HPV genotyping on oral cytology brushings.
Methods: Newly diagnosed OPC patients and their sexual partners underwent oral mouth swabs and answered a
risk factor questionnaire. Patient tumor samples and oral swabs from both the patient and partner were assessed
for HPV status and genotyped using Easy-Chip HPV Blot PCR.
Results: We enrolled 227 patient-partner pairs and obtained sufficient analyzable DNA from both members in
198 pairs. Of 144 patients with available OPC tumor tissue, 128 (89 %) had HPV-positive tumors by either in situ
hybridization or p16 immunohistochemical analysis (104 or 121, respectively). In total, there were 28 patients and 30
partners who were HPV positive by oral swab. The prevalence rate of oral HPV in partners was 15 %. There were
39 patient-partner pairs who had one or both members returning positive for HPV in the oral swab, and 49 % of
these pairs were concordant for their HPV-genotype. Female partners had a higher oral HPV prevalence (16 %)
than did male partners (11 %). Patients who were non-white were also found to have a higher oral prevalence of
HPV (p = 0.032) by mouth swab.
Conclusions: Partners of OPC patients may have a higher prevalence of oral HPV and should be studied
prospectively to understand their OPC risk. Additional future research is needed to identify oral HPV persistence
in partners to OPC patients and to determine the optimal sampling methods and technologies to screen patients
at high risk for HPV-related disease.
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Background
Human papillomavirus (HPV) is a known causative fac-
tor in most cervical premalignant and malignant condi-
tions and in oropharyngeal squamous cell cancers [1, 2].
While genital HPV transmission between women with
cervical cancer and their partners has been well studied
[3], there is limited data on the rates of oral HPV trans-
mission between patients with oropharyngeal cancer
(OPC) and their partners. Even less is known about the
oral transmission rate of specific HPV genotypes.
Prior cervical cancer studies have explored oral HPV
transmission between female patients and their partners.
A population-based Swedish study reported that hus-
bands of wives with cervical cancer had an increased
standardized incidence ratio of 2.7:1 of developing ton-
sillar or tongue cancer, while husbands of women with
cervical intraepithelial neoplasia had a ratio of 2.4:1 [4].
Although compelling, this trial was limited by it’s retro-
spective nature and dependence on the Swedish Family
Cancer Database, which did not account for oropharyn-
geal cancer risk factors such as tobacco and alcohol use.
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D’Souza et al. [5] recently published a prospective study
analyzing oral mouth rinse samples from 98 partners of
OPC patients and reported a low prevalence rate of
4.3 % oral HPV positivity.
Although the mechanism of HPV carcinogenesis is
complex and involves multiple factors, it is reasonable to
hypothesize that high-risk HPV genotypes are transmit-
ted between intimate partners and that this may predis-
pose both partners to certain HPV-related malignancies
(oropharyngeal, genital, or anal). We conducted a pro-
spective screening study of patients with OPC and their
partners to evaluate the prevalence of oral HPV via a
non-invasive technique, genotyped the identified oral
HPV, and assessed which risk factors (i.e., alcohol and
tobacco use) may be associated with increased transmis-
sion rates.
Methods
A prospective collection of oral (oral cavity and orophar-
ynx) epithelial cells was obtained by cytology brushing/
oral mouth swab in sequentially identified newly diag-
nosed patients with OPC and their partners treated at
MD Anderson Cancer Center (2007–2010). The eligibil-
ity criteria included informed consent from both the pa-
tient and partner, and a confirmed histologic diagnosis
of oropharyngeal squamous cell cancer in the patient.
Patient-partner pairs were excluded from this analysis if
the patient had received any prior radiation or chemo-
therapy for the OPC. Also, neither the patient nor part-
ner could have any clinical evidence of an active fungal,
viral, or other infection that could compromise the oral
swab results. Archived tumor tissue from prior diagnos-
tic biopsies was collected and subjected to standard
HPV testing via in situ hybridization (ISH) or p16 im-
munohistochemical analysis (IHC). A research assistant
administered a 2-page questionnaire to the patient and
partner that consisted of a detailed smoking history,
prior HPV-related disease history, sexual transmitted
disease infection history, and other oropharyngeal cancer
risk factors, such as mouth-wash and alcohol usage.
Patients and partners filled out the questionnaire at the
same time but were allowed to answer the question-
naires independently and privately. The questionnaire
requested information on any prior HPV-related diseases
included abnormal pap smears, cervical intraepithelial
neoplasia, cervical cancer, anal cancer, anogenital warts,
prior head and neck cancer, OPC, or penile cancer. This
study was approved by the MD Anderson institutional
review board.
The primary goal of this study was to determine the
prevalence of oral HPV presence, as determined by oral
mouth swabs via cytology brushings, in OPC patients
and their sexual partners. The secondary goals were to
1) characterize the HPV genotypes, 2) identify any risk
factors that are associated with high-risk HPV oral
prevalence, and 3) collect prior HPV-related disease in-
formation from partners.
For the mouth swabs, oral cytology brushes were used
to gently scrape the oral mucosa at the following posi-
tions: right buccal mucosa (vertically from the high to
low position), left buccal mucosa (vertically high to low
position), right side of tongue, dorsal side of tongue, left
side of tongue, and inside upper and lower lips. The ton-
sillar and base of tongue areas were then also gently
scraped. If a visible tumor was present, the brush was
used to gently scrape the tumor. The brush containing
exfoliated cells was placed in a clearly labeled tube con-
taining SurePath preservative fluid (<24 % denatured
ethanol and 1.2 % methanol; BD Diagnostics, Tripath
Imaging, Burlington, NC). The material was spun down
to a cell pellet, placed in alcohol-based solution, frozen,
and reserved as a back-up source of tissue specimen, if
needed for analysis. Collected oral cytology specimens
were frozen at –80 °C for batched HPV analysis.
DNA was extracted from SurePath Pap specimens using
the DNeasy kit (catalog no. 69506, Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions. Speci-
mens with positive results on consensus primer-mediated
PCR were genotyped using Easy-Chip HPV Blot (King
Car Yuanshan Research Institute, I-Lan, Taiwan) as de-
scribed previously [6]. First, HPV DNA was amplified by
PCR assay using modified MY11/GP6t biotinylated con-
sensus primer sets to amplify a fragment of 192 bp in the
L1 open reading frame of HPV and GAPDHF/GAPDHR
biotinylated primer sets were used to amplify a 136-bp
segment for specimen validation as described previously
[7, 8]. Briefly, PCR for HPV DNA was performed in a
PCR master mixture containing 20-ng aliquot of genomic
DNA, 15 mM Tris-HCl (pH 8.0), 2.0 mM MgCl2, 50 mM
KCl, 0.25 mM each deoxynucleoside triphosphate,
0.6 mM primer, and 0.5 units of DNA polymerase (HP
High Performance HotStart Taq DNA Polymerase; DNA
Technologies Ltd., UK). PCR assay was performed as
follows: 10 min at 95 °C, followed by 40 cycles of 30 s at
95 °C, 30 s at 45 °C, and 30 s at 72 °C and a final extension
of 5 min at 72 °C. PCR for GAPDH was performed
in a final reaction volume of 25 ml with a 10-ng
aliquot of genomic DNA in a PCR master mixture
containing 15 mM Tris-HCl (pH 8.0), 2.5 mM MgCl2,
50 mM KCl, 0.2 mM each deoxynucleoside triphos-
phate, 0.2 mM primer, and 0.5 units of HotStart Taq
DNA Polymerase (DNA Technologies Ltd., UK). PCR
assay was performed as follows: 10 min at 951C,
followed by 40 cycles of 15 s at 95 °C, 1 min at 57 °C, and
30 s at 72 °C and a final extension of 5 min at 72 °C. A 5-
ml aliquot of PCR products was analyzed by electrophor-
esis on a 2 % agarose gel and stained with ethidium
bromide.
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EasyChip HPV blot were designed to detect 39 HPV
types (HPV 6, 11, 16, 18, 26, 31, 32, 33, 35, 37, 39, 42,
43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 67,
68, 69, 70, 72, 74, 82, CP8061, CP8304, L1AE5, MM4,
MM7 and MM8 as well as three intrinsic controls). The
HPV type-specific probes were immobilized on a
14.4x9.6 mm nylon membrane, which was used for
reverse-blot hybridization to detect HPV DNA in a sin-
gle assay. The hybridization was performed according to
the manufacturer’s instructions. Briefly, the blot mem-
brane was equilibrated with 2x saline-sodium citrate
(SCC, 1xSCC containing 0.15 M NaCl and 0.015 M so-
dium citrate) at room temperature for 10 min. The blot
was preincubated in hybridization buffer (2xSSC, 0.5 %
blocking reagent, 5 % dextran sulfate, 0.1 % sodium do-
decyl sulfate (SDS), 50 mg/ml denatured salmon sperm
DNA) with shaking at 35 °C for 30 min. The membrane
was hybridized with 500 ml of hybridization buffer con-
taining 20 ml of the denatured amplicons (15 ml HPV
and 5 ml GAPDH PCR products) by shaking at 35 °C
for at least 3 h. The blot was washed two times in wash-
ing buffer 1 (2x SSC, 0.1 % SDS) for 5 min at 251 °C and
then washed two times in washing buffer 2 (0.2xSSC,
0.1 % SDS) for 5 min at 351 °C. The blot was equili-
brated with buffer 1 (1x phosphate-buffered saline,
pH 7.4, 0.05 % Tween 20, 0.1 % SDS) by shaking at 25 °
C for 5 min and then buffer 2 (1x phosphate-buffered
saline, pH 7.4, 0.05 % Tween 20, 0.1 % SDS, 0.5 % block-
ing reagent) at 25 °C for 1 h. The blot was incubated in
500 ml of buffer 2 containing streptavidin-AP (Calbio-
chem; alkaline phosphatase conjugates and biotinylated
antibodies, 1:1000 dilution) at 25 °C for 40 min. The blot
was then washed in buffer 1 and rinsed with buffer 3
(0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl) for 5 min. Then,
80 ml NBT/BCIP (5-bromochloro- 3-indolyl-phospate
and nitroblue tetrazolium) was added and incubated for
30 min at 25 °C. The reaction was terminated by adding
distilled water. The HPV types were determined by vis-
ual assessment protocol provided by King Car Yuanshan
Research Institute.
Statistical methods
Chi-square or Fisher exact test was used to assess the
differences in categorical variables, and the Wilcoxon
rank-sum or Kruskal-Wallis test was used to detect the
differences for continuous variables between the differ-
ent cohorts [9]. The sensitivity and specificity of the oral
swab compared to the tumor HPV status (by ISH or
IHC) was calculated with exact 95 % confidence inter-
vals (CIs). Simple kappa [9], an index of the proportion
of agreement beyond that expected by chance, was used
to assess the agreement of genotypes between patient-
partner pairs in which both parties were HPV positive
by mouth swabs. A point estimate and a 2-sided 95 % CI
of the kappa were provided.
Results
This study enrolled 227 patient-partner pairs (n = 454
persons) from 2007 to 2010. The demographic informa-
tion, exposure variables, and HPV medical history for
the full cohort enrolled are presented in Additional
file 1: Table S1. After DNA extraction and quality
control assessment of the DNA obtained from the oral
swabs, we determined that sufficient analyzable DNA was
available from both parties for 198 patient-partner pairs
(Fig. 1). There were no significant demographic differ-
ences between the 29 pairs (13 %) without adequate DNA
and the final analyzable 198 pairs, except that the
Fig. 1 Consort diagram
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excluded pairs were older (p = 0.04 and p = 0.022, respect-
ively; Additional file 1: Table S1). Due to lack of tumor tis-
sue availability, only 144 OPC patients had adequate
tumor tissue available for HPV testing and 128 (89 %) had
HPV-positive tumors by ISH or p16 IHC (104 and 121, re-
spectively) (Fig. 1).
In 39 of the 198 (20 %) patient-partner pairs, one or
both members had an HPV-positive oral swab. In total,
28 patients (14 %) were HPV positive by oral swab, and
30 partners were HPV positive (Table 1). Partners to
OPC patients had an oral HPV prevalence rate of 15 %.
High-risk HPV, defined in Gillison et al. [3] was detected
on oral swabs from 15 (12 %) patients with HPV-
positive OPC (9 of 15 were HPV 16). Although there
were only a few patients with HPV-negative tumors, a
similar proportion (13 %) of patients were found to be
HPV positive on oral swabs (Table 1).
Oral HPV16 was more commonly detected among pa-
tients than partners (9 and 6 %, respectively), and there
was a strong correlation between the oral HPV status of
the paired patients and partners (p < 0.001). However, in
the partners, the oral HPV prevalence was identical be-
tween the partners of patients with HPV-positive tumors
and the partners of those with HPV-negative tumors
(both 13 %; Table 1 and Fig. 1). We evaluated other
demographic features of the partners and discovered
that female partners had a higher oral HPV prevalence
(16 %) than did male partners (11 %). However, since
there were only 38 male partners in this study, the small
numbers did not reach statistical significance.
In the genotype analysis from the patient oral swabs,
the most common genotypes were HPV 16 and HPV 56
(17 of 28 (61 %) and 14 of 28 (50 %), respectively). In
the partners, HPV56 was the most common genotype
detected (15 of 30 (50 %)), with HPV16 being the second
most common (12 of 30 (40 %)). There were also several
cases of multiple genotypes identified among both pa-
tients and partners with a positive oral swab (17 of 28
(61 %) and 14 of 30 (47 %), respectively) (Table 1).
The demographics, risk factor exposure, and HPV-
related disease history of patients and partners, segre-
gated by oral swab HPV status, are presented in Table 2.
The only significant finding was that non-white patients
had a higher oral swab HPV prevalence than white pa-
tients (p = 0.032). There were no other significant differ-
ences among patients or partners between those with
and without detectable oral HPV (Table 2).
Table 3 presents the concordance rates of HPV status
between patient and partner pairs (i.e., both positive,
both negative, or discordant) and is also segregated by
HPV genotype. Nineteen couples had both members
demonstrate an HPV-positive oral swab (Table 2).
Within these 19 couples, genotype analysis showed that
11 (58 %) were both positive for HPV16, eight (42.1 %)
were both positive for HPV 56 (four in conjunction with
HPV16), and nine were positive for multiple HPV geno-
types (Table 3). The genotype results did not signifi-
cantly change when evaluating couples where the patient
had a documented HPV-positive tumor or when assesing
those couples with a female partner (Table 3). However,
Table 1 Prevalence of HPV in oral mouth swabs from partners and patients, stratified by tumor HPV status and sex
HPV mouth swab PCR result All patient-partner pairs (N = 198) HPV-negative tumor patient-partner
pairs (N = 16)
HPV-positive tumor patient-partner
pairs (N = 128)
Partners, N (%a) Patients, N (%) P* Partners, N (%) Patients, N (%) P* Partners, N (%) Patients, N (%) P*
All negative 168 (84.9) 170 (85.9) 14 (87.5) 14 (87.5) 111 (86.7) 113 (88.3)
Oncogenic HPV positive 30 (15.2) 28 (14.1) 0.66 2 (12.5) 2 (12.5) 1.00 17 (13.3) 15 (11.7) 0.77
HPV16 positive 12 (6.1) 17 (8.6) 0.13 0 (0.0) 1 (6.3) NA 5 (3.9) 9 (7.0) 0.13
Other HPV genotype positive 27 (13.6) 26 (13.1) 0.83 2 (12.5) 2 (12.5) 1.00 15 (11.7) 14 (10.9) 0.78
Multiple (≥2) genotypes positive 14 (7.1) 17 (8.6) 0.58 1 (6.3) 2 (12.5) 1.00 5 (3.9) 8 (6.3) 0.45
Female partners and male patients
HPV mouth swab PCR result All male patient-female
partner pairs (N = 160)
HPV-negative tumor male patient-
female partner pairs (N = 13)
HPV-positive tumor male patient-
female partner pairs (N = 101)
Partners, N (%a) Patients, N (%) P* Partners, N (%) Patients, N (%) P* Partners, N (%) Patients, N (%) P*
All negative 134 (83.8) 137 (85.6) 11 (84.6) 11 (84.6) 85 (84.2) 88 (87.1)
Oncogenic HPV positive 26 (16.3) 23 (14.4) 0.49 2 (15.4) 2 (15.4) 1.00 16 (15.8) 13 (12.9) 0.55
HPV16 positive 10 (6.3) 14 (8.8) 0.22 0 (0.0) 1 (7.7) NA 5 (5.0) 8 (7.9) 0.25
Other HPV genotype positive 23 (14.4) 21 (13.1) 0.65 2 (15.4) 2 (15.4) 1.00 14 (13.9) 12 (11.9) 0.56
Multiple (≥2) genotypes positive 12 (7.5) 14 (8.8) 0.77 1 (7.7) 2 (15.4) 1.00 5 (5.0) 7 (6.9) 0.69
*McNemar test (asymptotic or exact)
aDenominators of all the percentages are the corresponding Ns in parentheses
NA = not assessed
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in couples who both had HPV-positive oral swabs, part-
ners were more likely to be older age ≥ 55 years than
partners with concordant negative results (68 % vs 42 %;
p = 0.03; Table 4). In addition, couples who were both
HPV positive by oral swabs were more likely to consist
of a non-white patient than couples with concordant
negative results (32 % vs 8 %, p = 0.002; Table 4). There
were no other significant differences in the distribution
of demographics, exposure, or HPV-related disease
history between couples with concordant positive and
concordant negative oral HPV prevalence.
Discussion
In this study of almost 200 OPC patients and their part-
ners, we identified an oral HPV prevalence rate of 15 %
among partners by oral swab sampling and a14 % rate
for patients. A high proportion (89 %) of OPC tumors
were positive for HPV when tested by HPV-ISH or p16
Table 2 Demographic data, exposure, and HPV-related disease history among participants segregated by oral swab statusf
Characteristic Patients (N = 198) Partners (N = 198)
Swab positive (N = 28) Swab negative (N = 170) p-Value Swab positive (N = 30) Swab negative (N = 168) p-value
Age, years
< 55 12 (42.9 %) 76 (44.7 %) .86 15 (50 %) 93 (56 %) .54
≥ 55 16 (57.1 %) 94 (55.3 %) 15 (50 %) 73 (44 %)
Sex
Female 5 (17.9 %) 32 (18.8 %) 1.0 26 (86.7 %) 135 (80.4 %) .61
Male 23 (82.1 %) 138 (81.2 %) 4 (13.3 %) 33 (19.6 %)
Race
White 22 (78.6 %) 156 (91.8 %) .032 23 (76.7 %) 134 (79.8 %) .70
Other 6 (21.4 %) 14 (8.2 %) 7 (23.3 %) 34 (20.2 %)
Smoking statusa
Former/never 14 (70.0 %) 80 (71.4 %) .90 13 (61.9 %) 61 (67.8 %) .61
Current 6 (30 %) 32 (28.6 %) 8 (38.1 %) 29 (32.2 %)
Prior alcohol useb
None 3 (11.1 %) 15 (8.9 %) .72 6 (20 %) 34 (21.1 %) .89
Yes 24 (88.9 %) 154 (91.1 %) 24 (80 %) 127 (78.9 %)
Prior HPV-related disease
None 28 (100.0 %) 157 (93.5 %) .37 23 (76.7 %) 133 (80.1 %) .67
Yes 0 (0.0 %) 11 (6.5 %) 7 (23.3 %) 33 (19.9 %)
Prior benign HPV-related diseasec
None 28 (100.0 %) 165 (97.1 %) 1.0 30 (100 %) 161 (95.8 %) .60
Yes 0 (0.0 %) 5 (2.9 %) 0 (0 %) 7 (4.2 %)
Prior HPV-related malignancyd
None 27 (96.4 %) 165 (97.1 %) 1.0 29 (96.7 %) 163 (97 %) 1.0
Yes 1 (3.6 %) 5 (2.9 %) 1 (3.3 %) 5 (3 %)
HPV status of oropharyngeal tumore
Negative 2 (11.8 %) 14 (11 %) 1.0 2 (10.5 %) 14 (11.2 %) 1.0
Positive 15 (88.2 %) 113 (89 %) 17 (89.5 %) 111 (88.8 %)
Oral mouth swab status of matched pair
HPV Negative 9 (32.1 %) 159 (93.5 %) <.001 11 (36.7 %) 159 (94.6 %) <.001
HPV Positive 19 (67.9 %) 11 (6.5 %) 19 (63.3 %) 9 (5.4 %)
a8 swab positive and 58 swab negative patients had missing data on smoking; 1 swab positive and 1 swab negative patient had missing data on prior alcohol use
b9 swab positive and 78 swab negative partners had missing data on smoking; 7 swab negative partners had missing data on prior alcohol use
cbenign HPV-related disease defined as CIN I-III, dysplasia
dCervical cancer, anal cancer, prior HNSCC cancer
eBy p16 IHC (N = 121) or HPV ISH (N = 104); data were unavailable for 54 patients
fPercentages are calculated as a column percentage
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IHC, consistent with the results of a prior large contem-
porary series from our institution [10]. In our patient
population, oral swab HPV testing had a low sensitivity
for determining HPV tumor status. We suspect that ra-
ther than detecting tumor HPV, we are detecting preva-
lent HPV infections being shared between patients and
partners. This is supported by the fact that we detected
oral HPV in approximately two-thirds of the partners of
HPV-positive oral mouth swab patients.
The oral HPV prevalence in partners (15 % overall and
16 % for female partners) was higher than that previ-
ously reported for the general population (7 and 4 % for
women) using National Health and Nutrition Examin-
ation Survey (NHANES) 2009–2010 [3] and in a re-
cently reported study of partners of OPC patients (4 and
2 % for female partners) [5]. This discrepancy could
potentially be explained by several reasons. First, our
sample size of partners was larger (n = 198) than that
(n = 93) recently reported by D’Souza et al [5]. Thus,
we may have a more stable estimate of oral HPV preva-
lence. Second, our patient population may have had
demographic differences that are linked to a higher oral
HPV prevalence. We did exclude 29 couples due to inad-
equate DNA quality by oral mouth swab, and these indi-
viduals were slightly older. However, of note, the median
age of our partners (age 53) was identical to that in the
D’Souza study. Our study did include a higher number of
male partners (19 %) and non-white partners (21 %) than
the D’Souza study (7 and 6 %, respectively). We also had a
higher number of partners who were current smokers and




All patient-partner pairs (N = 198) HPV-negative tumor patient-partner
pairs (N = 16)
HPV-positive tumor patient-partner



















High-risk HPV 19 (9.6) 159 (80.3) 20 (10.1) 1 (6.3) 13 (81.3) 2 (12.5) 10 (7.8) 106 (82.8) 12 (9.4)
HPV16 11 (5.6) 180 (90.9) 7 (3.5) 0 (0.0) 15 (93.8) 1 P (6.3) 5 (3.9) 119 (93.0) 4 (3.1)
HPV18 2 (1.0) 195 (98.5) 1 (0.5) 1 (6.3) 15 (93.8) 0 (0.0) 1 (0.8) 127 (99.2) 0 (0.0)
HPV31 0 (0.0) 196 (99.0) 2 (1.0) 0 (0.0) 15 (93.8) 1 P (6.3) 0 (0.0) 127 (99.2) 1 (0.8)
HPV39 0 (0.0) 197 (99.5) 0 (0.0) 1 (6.3) 15 (93.8) 0 (0.0) 0 (0.0) 128 (100.0) 0 (0.0)
HPV43 0 (0.0) 197 (99.5) 1S (0.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 127 (99.2) 1 (0.8)
HPV45 0 (0.0) 193 (97.5) 5 (2.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 126 (98.4) 2 (1.6)
HPV51 0 (0.0) 197 (99.5) 1 P (0.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 128 (100.0) 0 (0.0)
HPV52 0 (0.0) 195 (98.5) 3 S (1.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 126 (98.4) 2 (1.6)
HPV54 0 (0.0) 195 (98.5) 3 (1.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 126 (98.4) 2 (1.6)
HPV56 8 (4.0) 177 (89.4) 13 (6.6) 0 (0.0) 14 (87.5) 2 (12.5) 5 (3.9) 115 (89.8) 8 (6.2)
HPV59 2 (1.0) 194 (98.0) 2 (1.0) 0 (0.0) 16 (100) 0 (0.0) 1 (0.8) 126 (98.4) 1 (0.8)
HPV61 0 (0.0) 195 (98.5) 3 (1.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 126 (98.4) 2 (1.6)
HPV67 1 (0.5) 194 (98.0) 3 (1.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 126 (98.4) 0 (0.0)
HPV70 0 (0.0) 197 (99.5) 1 S (0.5) 0 (0.0) 16 (100) 0 (0.0) 0 (0.0) 128 (100.0) 0 (0.0)
HPV84 0 (0.0) 195 (98.5) 3 S (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 128 (100.0) 0 (0.0)
Multiple types
(≥2)
9 (4.6) 176 (88.9) 13 (6.6) 1 (6.3) 14 (87.5) 1 (6.3) 3 (2.3) 118 (92.2) 7 (5.5)
Female partners of male patients



















High-risk HPV 15 (9.4) 126 (78.8) 19 (11.9) 1 (7.7) 10 (76.9) 2 (15.3) 9 (8.9) 81 (80.2) 11 (10.9)
HPV16 9 (5.6) 145 (90.6) 6 (3.8) 0 (0.0) 12 (92.3) 1 P (7.7) 5 (5.0) 93 (92.1) 3 (3.0)
Other HPV
types
12 (7.5) 128 (80.0) 20 (12.58) 1 (7.7) 10 (76.9) 2 (15.3) 7 (6.9) 82 (81.2) 12 (11.9)
Multiple types
(≥2)
7 (4.4) 141 (88.1) 12 (7.5) 1 (7.7) 11 (84.6) 1 (7.7) 3 (3.0) 92 (91.1) 6 (5.9)
*Denominators of the percentages are the corresponding Ns in the parentheses
S indicates partner/spouse; P indicates patient
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drinkers (33 % and 79 %, respectively) compared to the
D’Souza et al. study, 12 % current smokers and 65 % alco-
hol drinkers. Both of these behaviors may be associated
with more high-risk sexual practices. In addition, we re-
ported a higher rate of prior HPV-related disease among
female partners (25 %) than that identified in the D’Souza
study (10 %) [5]. Unfortunately, a significant limitation of
our study was that we lacked clinical data on sexual prac-
tices and lifetime oral and genital sex partners, which
could have also contributed to the higher prevalence of
oral HPV. Third, our detection method, using an oral
mouth swab with a cytology brush and swabbing eight or
Table 4 Demographics, exposure, and HPV-related disease history of HPV concordant positive and negative pairs
Characteristic All patient-partner pairs+ (N = 198)
Concordant positive (N = 19) Concordant negative (N = 159) p-value*
Patient age, years
< 55 7 (36.8 %) 69 (43.4 %) .59
≥ 55 12 (63.2 %) 90 (56.6 %)
Partner age, years
< 55 6 (31.6 %) 91 (57.6 %) .03
≥ 55 13 (68.4 %) 67 (42.4 %)
Patient sex
F 4 (21.1 %) 32 (20.1 %) 1.0
M 15 (78.9 %) 127 (79.9 %)
Partner sex
F 15 (78.9 %) 127 (79.9 %) 1.0
M 4 (21.1 %) 32 (20.1 %)
Patient race
White 13 (68.4 %) 146 (91.8 %) .002
Other 6 (31.6 %) 13 (8.2 %)
Partner race
White 13 (68.4 %) 125 (78.6 %) .31
Other 6 (31.6 %) 34 (21.4 %)
Patient smoking status
Former/never 8 (61.5 %) 76 (71.7 %) .52
Current 5 (38.5 %) 30 (28.3 %)
Partner smoking status
Former/never 7 (53.8 %) 58 (66.7 %) .37
Current 6 (46.2 %) 29 (33.3 %)
Patient history of benign HPV disease
None 19 (100 %) 154 (96.9 %) 1.0
Yes 0 (0 %) 5 (3.1 %)
Partner history of benign HPV disease
None 19(100 %) 153 (96.2 %) 1.0
Yes 0 (0 %) 6 (3.8 %)
Patient history of HPV cancer
None 18 (94.7 %) 155 (97.5 %) .44
Yes 1 (5.3 %) 4 (2.5 %)
Partner history of HPV cancer
None 19 (100 %) 155 (97.5 %) 1.0
Yes 0 (0 %) 4 (2.5 %)
*Fisher’s exact test
+Percentages are all column percentages
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nine areas within the oral cavity and oropharynx, may
have been more aggressive than those used in prior re-
ports [3, 5] where oral rinses were typically used.
Our results suggest that partners of OPC patients have
a higher oral HPV prevalence than that found in the
general population [3]. However, whether this higher
oral HPV prevalence will ultimately translate into a
significantly higher risk of HPV-associated OPC is un-
known and requires additional study. Dalla Torre et al.
[11] has previously reported that high-risk oral HPV
infections are associated with the presence of oral pre-
malignant lesions. It can be extrapolated that since per-
sistent cervical HPV status is directly linked to a higher
risk of progression to high-grade cervical intraepithelial
neoplasia and cervical cancer, it is critical that we under-
stand the natural history of oral HPV infections and
investigate the significance of persistent oral infections.
High oral HPV16 load has been reported to be associ-
ated with a longer time to clearance of infection [12]. In
the HPV Infection in Men (HIM) cohort study [13],
which evaluated 1626 men over 1 year, newly acquired
oral HPV16 infections were identified in 0.6 % (n = 18),
and most of the infections had cleared after 1 year.
However, eight of these men had persistent infections
for the entire study duration. A population with persist-
ently detected oral HPV would be an ideal group in
which to study novel screening technologies.
One of the issues that requires more investigation is
identifying the optimal screening method. Kreimer et al.
[14] reported that blood HPV16 E6 seropositivity was
identified in 35 % of OPC patients and was found more
than 10 years prior to the cancer diagnosis. Rettig et al.
[15] evaluated 124 definitively treated HPV-positive
OPC patients and obtained oral rinse and gargle samples
at 9, 12, 18, and 24 months after therapy. They reported
that five patients with persistent oral HPV16 status had
poorer disease-free survival (more local recurrence) and
overall survival. However, while the specificity of the oral
rinse and gargle was 100 %, the sensitivity was only
43 %; suggesting that the optimal screening method re-
mains unknown. Taken together with this growing body
of literature [3, 16, 17], the results of our study suggest
that the method of sampling is important and that oral
mouth swabs with aggressive sampling are a better
methodology to be explored with other testing strategies,
such as serology [14, 18] or potentially ultrasound [19]
evaluation.
Conclusion
Partners of OPC patients may have a higher prevalence
of oral HPV and should be studied prospectively to re-
fine our understanding of OPC risk among these indi-
viduals. Future research is needed to determine oral
HPV persistence in partners, optimal sampling methods
for oral HPV, and possible technologies for screening
these patients who are at higher risk for HPV-related
disease.
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